Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections
| Autor: | Carisa De Anda, Mohammed S Tayob, Jason Y Kim, Natasha Broyde, Tinatin Antadze, Borislav Ninov, Pamela Sears, Joan R. Butterton, Margaret Z Chou, John S. Bradley |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Microbiology (medical) medicine.medical_specialty Standard of care Adolescent Active Comparator Tetrazoles Phases of clinical research Global Health Clinical success 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 030225 pediatrics Internal medicine medicine Clinical endpoint Humans 030212 general & internal medicine Adverse effect Oxazolidinones business.industry Soft Tissue Infections Skin Diseases Bacterial Abscess Anti-Bacterial Agents Infectious Diseases chemistry Pediatrics Perinatology and Child Health Wound Infection Skin structure Female Tedizolid business |
| Zdroj: | Pediatric Infectious Disease Journal. 40:238-244 |
| ISSN: | 0891-3668 |
| DOI: | 10.1097/inf.0000000000003010 |
| Popis: | BACKGROUND Tedizolid phosphate is an oxazolidinone prodrug approved in 2014 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs); however, efficacy has not previously been evaluated in children. This study compared the safety and efficacy of tedizolid (administered as tedizolid phosphate) with active antibacterial comparators for the treatment of ABSSSIs in adolescents. METHODS This was a randomized, assessor-blind, global phase 3 study of tedizolid versus active comparators for the treatment of Gram-positive ABSSSIs in adolescents (12 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|